Clusters of differentiation

France: OSE Immunotherapeutics enters a loan agreement of up to €25 million with the EIB

Retrieved on:

Monday, February 15, 2021

Medical specialties, Clinical medicine, Medicine, Immune system, Clusters of differentiation, Immunology, Cancer immunotherapy, Monoclonal antibodies, CD47, Boehringer Ingelheim, Checkpoint inhibitor, Programmed cell death protein 1

Vaccine platformTedopi® (innovative combination of neoepitopes): the company’s most advanced product; positive results for Step-1 of the Phase 3 trial (Atalante 1) in Non-Small Cell Lung Cancer post checkpoint inhibitor failure. In Phase 2 in pancreatic cancer (TEDOPaM, sponsor GERCOR) in combination. Due to the COVID-19 crisis, accrual of new patients in TEDOPaM should restart in 2021.CoVepiT: a prophylactic second generation vaccine against COVID-19, developed using SARS-CoV-2 optimized epitopes against multi variants. Positive preclinical and human ex vivo results in August 2020, clinical trial expected to start in Q1 2021.Immuno-oncology platformBI 765063 (OSE-172, anti-SIRPα mAb on SIRPα/CD47 pathway): developed in partnership with Boehringer Ingelheim; myeloid checkpoint inhibitor in Phase 1 in advanced solid tumors.CLEC-1 (novel myeloid checkpoint target): identification of mAb antagonists of CLEC-1 blocking the “Don’t Eat Me” signal that increase both tumor cell phagocytosis by macrophages and antigen capture by dendritic cells.BiCKI®: bispecific fusion protein platform built on the key backbone component anti-PD-1 (OSE-279) combined with new immunotherapy targets; 2nd generation of PD-(L)1 inhibitors to increase antitumor efficacity.Auto-immunity and inflammation platformFR104 (anti-CD28 monoclonal antibody): positive Phase 1 results; ongoing Phase 1/2 in renal transplant, Phase 2-ready asset in a niche indication in autoimmune diseases.OSE-127/S95011 (humanized monoclonal antibody targeting IL-7 receptor): developed in partnership with Servier; positive Phase 1 results; in Phase 2 in ulcerative colitis (OSE sponsor) and an independent Phase 2 planned in Sjögren’s syndrome (Servier sponsor).OSE-230 (ChemR23 agonist mAb): first-in-class therapeutic agent with the potential to resolve chronic inflammation by driving affected tissues to tissue integrity.

Key Points:

Vaccine platform

Tedopi® (innovative combination of neoepitopes): the company’s most advanced product; positive results for Step-1 of the Phase 3 trial (Atalante 1) in Non-Small Cell Lung Cancer post checkpoint inhibitor failure. In Phase 2 in pancreatic cancer (TEDOPaM, sponsor GERCOR) in combination. Due to the COVID-19 crisis, accrual of new patients in TEDOPaM should restart in 2021.
CoVepiT: a prophylactic second generation vaccine against COVID-19, developed using SARS-CoV-2 optimized epitopes against multi variants. Positive preclinical and human ex vivo results in August 2020, clinical trial expected to start in Q1 2021.

Immuno-oncology platform

BI 765063 (OSE-172, anti-SIRPα mAb on SIRPα/CD47 pathway): developed in partnership with Boehringer Ingelheim; myeloid checkpoint inhibitor in Phase 1 in advanced solid tumors.
CLEC-1 (novel myeloid checkpoint target): identification of mAb antagonists of CLEC-1 blocking the “Don’t Eat Me” signal that increase both tumor cell phagocytosis by macrophages and antigen capture by dendritic cells.
BiCKI®: bispecific fusion protein platform built on the key backbone component anti-PD-1 (OSE-279) combined with new immunotherapy targets; 2nd generation of PD-(L)1 inhibitors to increase antitumor efficacity.

Auto-immunity and inflammation platform

FR104 (anti-CD28 monoclonal antibody): positive Phase 1 results; ongoing Phase 1/2 in renal transplant, Phase 2-ready asset in a niche indication in autoimmune diseases.
OSE-127/S95011 (humanized monoclonal antibody targeting IL-7 receptor): developed in partnership with Servier; positive Phase 1 results; in Phase 2 in ulcerative colitis (OSE sponsor) and an independent Phase 2 planned in Sjögren’s syndrome (Servier sponsor).
OSE-230 (ChemR23 agonist mAb): first-in-class therapeutic agent with the potential to resolve chronic inflammation by driving affected tissues to tissue integrity.

Elicio Therapeutics to discuss success of Amphiphiles enabled T cell therapies at CAR-TCR Digital Summit Europe

Retrieved on:

Monday, February 15, 2021

Activation of CAR-T cells with Amphiphiles delivered to the lymph nodes to induce massive CAR-T expansion.

Key Points:

Activation of CAR-T cells with Amphiphiles delivered to the lymph nodes to induce massive CAR-T expansion.
Elicio is developing the AMP-CAR-T platform for combination with CAR-T cell therapies in a variety of settings including those targeting CD19, BCMA, and several solid tumor indications.
Elicio Therapeutics is advancing the Amphiphile technology across immunotherapy platforms to defeat cancers and infectious diseases.
Elicio is engineering lymph node targeted cell therapy activators, immunomodulators, adjuvants and vaccines for an array of aggressive cancers and infectious diseases.

Basilea reports derazantinib/PD-L1 checkpoint inhibitor combination results from dose-finding part of FIDES-02 study in patients with solid tumors at ASCO GU symposium

Retrieved on:

Friday, February 12, 2021

Branches of biology, Clinical medicine, Medicine, Breakthrough therapy, Orphan drugs, Cancer immunotherapy, Immune system, Clusters of differentiation, Atezolizumab, Checkpoint inhibitor, Colony stimulating factor 1 receptor, Macrophage colony-stimulating factor

The combination of derazantinib and atezolizumab is supported by preclinical data demonstrating derazantinibs strong inhibition of colony-stimulating-factor-1-receptor kinase (CSF1R).

Key Points:

The combination of derazantinib and atezolizumab is supported by preclinical data demonstrating derazantinibs strong inhibition of colony-stimulating-factor-1-receptor kinase (CSF1R).
CSF1R inhibition may revert tumor-induced immunosuppression and thereby enhance the response to immune-checkpoint inhibition.
The following e-poster was presented at ASCO GU 2021:
Derazantinib (DZB) in combination with atezolizumab (AZB) in patients with solid tumors: Results from the dose-finding phase Ib substudy of FIDES-02.
The first study, FIDES-01, is a registrational phase 2 study in patients with inoperable or advanced iCCA.

Infinity Pharmaceuticals Presents Data from Randomized, Placebo-Controlled, Phase 2 MARIO-275 Trial of Eganelisib and Nivolumab in Advanced Urothelial Cancer at ASCO Genitourinary Cancers Symposium

Retrieved on:

Thursday, February 11, 2021

Biotechnology, Health, Pharmaceutical, Clinical trials, Oncology, Drugs, Clinical medicine, Breakthrough therapy, Medicine, Monoclonal antibodies, Antineoplastic drugs, Clusters of differentiation, Cancer immunotherapy, Orphan drugs, Nivolumab, PD-L1, Transitional cell carcinoma

The objective of MARIO-275 was to address the need for better treatments for second line (2L) advanced UC patients.

Key Points:

The objective of MARIO-275 was to address the need for better treatments for second line (2L) advanced UC patients.
This is a promising advancement that has the potential to address the significant needs of PD-L1 low patients, which represent the majority of metastatic urothelial cancer population.
Infinity is advancing eganelisib, a first-in-class, oral immuno-oncology development candidate that selectively inhibits PI3K-gamma, in multiple clinical studies.
MARIO-275 is a global, randomized, placebo-controlled combination study of eganelisib combined with Opdivo in I/O nave urothelial cancer.

Basilea reports positive topline results from phase 2 study FIDES-01 for derazantinib in FGFR2 gene fusion-positive patients with bile duct cancer (iCCA)

Retrieved on:

Wednesday, February 10, 2021

Tyrosine kinase receptors, Clusters of differentiation, Fibroblast growth factor receptor 2

Enrolment into cohort 2 of FIDES-01 is ongoing, assessing the activity of derazantinib in iCCA patients with FGFR2 gene mutations or amplifications.

Key Points:

Enrolment into cohort 2 of FIDES-01 is ongoing, assessing the activity of derazantinib in iCCA patients with FGFR2 gene mutations or amplifications.
The disease control rate (DCR), reflecting the proportion of patients with a partial response or with stable disease, was 72.8%.
The results are not yet fully mature, as 12 patients are still ongoing, including 3 patients with a partial response.
The first study, FIDES-01, is a phase 2 study in patients with inoperable or advanced iCCA.

FDA Approves Libtayo® (cemiplimab-rwlc) as First Immunotherapy Indicated for Patients with Advanced Basal Cell Carcinoma

Retrieved on:

Tuesday, February 9, 2021

Clusters of differentiation, Immune system, Medical specialties, Regeneron Pharmaceuticals, Programmed cell death protein 1, PD-L1, Medicine, Clinical medicine

By binding to PD-1, Libtayo has been shown to block cancer cells from using the PD-1 pathway to suppress T-cell activation.

Key Points:

By binding to PD-1, Libtayo has been shown to block cancer cells from using the PD-1 pathway to suppress T-cell activation.
No PD-L1 or tumor mutational burden (TMB) testing is required before starting treatment with Libtayo for advanced BCC.
Outside of the U.S., the generic name for Libtayo in its approved indication is cemiplimab.
Libtayo was invented using Regeneron's VelocImmune technology that utilizes a proprietary genetically-engineered mouse platform endowed with a genetically-humanized immune system to produce optimized fully-human antibodies.

Agenus Announces New Responses for AGEN1181

Retrieved on:

Tuesday, February 9, 2021

T cells, Branches of biology, Clinical medicine, Clusters of differentiation, Medicine, Cancer immunotherapy, Bristol-Myers Squibb, Ipilimumab, Agenus, CTLA-4, Regulatory T cell, Immunotherapy

These are very exciting results which demonstrate the potential of AGEN1181 as an efficacious next-generation CTLA-4 antibody.

Key Points:

These are very exciting results which demonstrate the potential of AGEN1181 as an efficacious next-generation CTLA-4 antibody.
AGEN1181 is showing activity in difficult-to-treat tumors without the neuroendocrine or significant liver toxicities commonly observed with the currently-approved CTLA-4 antibody ipilimumab, said Dr. Steven ODay, Chief Medical Officer at Agenus.
The responses seen in patients with ovarian and MSS colorectal cancer are particularly encouraging given the generally low activity seen with immunotherapy in these indications.
Agenus also presented on the first-ever report of intratumoral Treg depletion with a CTLA-4 antibody in clinical trials at SITC 2020.

Arch Oncology to Collaborate with Merck on Phase 1/2 Clinical Trial of Anti-CD47 Antibody AO-176 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Select Solid Tumors

Retrieved on:

Tuesday, February 9, 2021

Cancer treatments, Clinical medicine, Medicine, Clusters of differentiation, Cancer immunotherapy, Antineoplastic drugs, Breakthrough therapy, Pembrolizumab, CD47, Programmed cell death protein 1, Mapatumumab

Under this collaboration, Arch Oncology is expanding its ongoing Phase 1/2 clinical trial to evaluate AO-176, the Companys novel anti-CD47 antibody, in combination with KEYTRUDA (pembrolizumab), Mercks anti-PD-1 therapy, for the treatment of patients with select solid tumors.

Key Points:

Under this collaboration, Arch Oncology is expanding its ongoing Phase 1/2 clinical trial to evaluate AO-176, the Companys novel anti-CD47 antibody, in combination with KEYTRUDA (pembrolizumab), Mercks anti-PD-1 therapy, for the treatment of patients with select solid tumors.
As a monotherapy, AO-176 demonstrated encouraging safety and evidence of anti-tumor activity in patients with select solid tumors.
AO-176 is being evaluated in Phase 1/2 clinical trials for the treatment of patients with select solid tumors and multiple myeloma, both as monotherapy and in combination with standard therapies.
In a Phase 1 trial in solid tumors, AO-176 demonstrated encouraging safety and evidence of anti-tumor activity when administered as a single agent.

Monopar Announces Issuance of Patent Covering Composition of Matter for MNPR-101 in Canada

Retrieved on:

Tuesday, February 9, 2021

Life sciences, Blood, Biotechnology, Clusters of differentiation, Urokinase receptor, Urokinase, Plasmin, Biopharmaceutical

This is an important advancement in our efforts to broaden our global patent estate for MNPR-101, said Chandler Robinson, MD, Chief Executive Officer of Monopar.

Key Points:

This is an important advancement in our efforts to broaden our global patent estate for MNPR-101, said Chandler Robinson, MD, Chief Executive Officer of Monopar.
MNPR-101 is a novel, first-in-class humanized monoclonal antibody to the urokinase Plasminogen Activator Receptor (uPAR).
We are excited about the approval of this composition of matter patent in Canada as it further enables us to explore the potential of MNPR-101 on a global scale, said Andrew Mazar, PhD, Chief Scientific Officer of Monopar.
Monopar Therapeutics is a clinical-stage biopharmaceutical companyprimarilyfocused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients.

I-Mab Announces Multiple Clinical Advancements of Its Differentiated CD73 Antibody Uliledlimab in China and the U.S.

Retrieved on:

Friday, February 5, 2021

Clusters of differentiation, Branches of biology, Medical specialties, NT5E, Biology, Tumor microenvironment, Adenosine monophosphate, Antibody, ENTPD1

Uliledlimab is a humanized CD73 antibody and works effectively on modulating tumor microenvironment through inhibition of the adenosine pathway.

Key Points:

Uliledlimab is a humanized CD73 antibody and works effectively on modulating tumor microenvironment through inhibition of the adenosine pathway.
Uliledlimab is shown to strongly suppress tumor growth especially when combined with a PD-(L)1 inhibitor in pre-clinical studies.
As a differentiated CD73 antibody, uliledlimab interacts with a unique epitope to function through a novel intra-dimer binding mode, thus enabling differentiated and favorable functional properties.
Uliledlimab (TJD5) is a differentiated, humanized antibody against CD73, an ecto-enzyme expressed on stromal cells and tumors that converts extracellular adenosine monophosphate (AMP) to adenosine.